<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1889">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470622</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-019-202</org_study_id>
    <nct_id>NCT04470622</nct_id>
  </id_info>
  <brief_title>Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to&#xD;
      standard of care for hospitalized patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects alive and discharged from the hospital.</measure>
    <time_frame>14 Days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).</measure>
    <time_frame>56 Days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from hospital.</measure>
    <time_frame>56 Days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Interleukin 6 (IL-6).</measure>
    <time_frame>Days 7, 14, 28, 56.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events.</measure>
    <time_frame>From signing ICF to Day 56.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant injectable emulsion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant injectable emulsion</intervention_name>
    <description>Aprepitant injectable emulsion, once daily (QD) for 14 days.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline Placebo, once daily (QD) for 14 days.</description>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is hospitalized for ≤24 hours with SARS-CoV-2 infection. confirmed by polymerase chain&#xD;
             reaction test.&#xD;
&#xD;
          -  Has oxygen saturation ≤93% by pulse oximetry on room air and requiring supplemental.&#xD;
             oxygen but not anticipated to require mechanical ventilation within 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is taking high-dose hydroxychloroquine or chloroquine.&#xD;
&#xD;
          -  Is taking pimozide or strong or moderate CYP3A4 inhibitors.&#xD;
&#xD;
          -  Is currently receiving treatment with products intended to modify immune resp)onse to&#xD;
             COVID-19 (exception: dexamethasone, methylprednisolone, or equivalent are allowed,&#xD;
             chemotherapy or on hemodialysis or peritoneal dialysis.&#xD;
&#xD;
          -  Has known hypersensitivity to any components of aprepitant injectable emulsion.&#xD;
&#xD;
          -  Has evidence of ARDS.&#xD;
&#xD;
          -  Is being treated with oxygen delivered by high-flow nasal cannula nonrebreather mask,&#xD;
             noninvasive positive pressure ventilation, or ECMO.&#xD;
&#xD;
          -  Has multiple organ failure.&#xD;
&#xD;
          -  Has current confirmed Influenza A or B infection, or a a history of organ or&#xD;
             hematologic transplant, HIV, or active hepatitis B or hepatitis C infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neil Clendeninn, PhD, MD</last_name>
    <phone>1-619-772-2641</phone>
    <email>nclendeninn@herontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann - Memorial City Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation</name>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

